Literature DB >> 26325031

Cancer immunotherapy: harnessing the immune system to battle cancer.

Yiping Yang.   

Abstract

The recent clinical successes of immune checkpoint blockade and chimeric antigen receptor T cell therapies represent a turning point in cancer immunotherapy. These successes also underscore the importance of understanding basic tumor immunology for successful clinical translation in treating patients with cancer. The Reviews in this Review Series focus on current developments in cancer immunotherapy, highlight recent advances in our understanding of basic aspects of tumor immunology, and suggest how these insights can lead to the development of new immunotherapeutic strategies.

Entities:  

Mesh：

Year:  2015        PMID： 26325031      PMCID： PMC4588312          DOI： 10.1172/JCI83871

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  32 in total

1.  Breakthrough of the year 2013. Cancer immunotherapy.

Authors:  Jennifer Couzin-Frankel
Journal:  Science       Date:  2013-12-20       Impact factor: 47.728

2.  CTLA-4 can function as a negative regulator of T cell activation.

Authors:  T L Walunas; D J Lenschow; C Y Bakker; P S Linsley; G J Freeman; J M Green; C B Thompson; J A Bluestone
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

3.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

Authors:  Renier J Brentjens; Jean-Baptiste Latouche; Elmer Santos; Francesc Marti; Michael C Gong; Clay Lyddane; Philip D King; Steven Larson; Mark Weiss; Isabelle Rivière; Michel Sadelain
Journal:  Nat Med       Date:  2003-02-10       Impact factor: 53.440

Review 4.  CAR therapy: the CD19 paradigm.

Authors:  Michel Sadelain
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

5.  Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors:  Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

6.  A new member of the immunoglobulin superfamily--CTLA-4.

Authors:  J F Brunet; F Denizot; M F Luciani; M Roux-Dosseto; M Suzan; M G Mattei; P Golstein
Journal:  Nature       Date:  1987 Jul 16-22       Impact factor: 49.962

7.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.

Authors:  Z Eshhar; T Waks; G Gross; D G Schindler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

8.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

9.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

10.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307
View more
  360 in total

1.  Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.

Authors:  Ahmed T Kurdi; Siobhan V Glavey; Natalie A Bezman; Amy Jhatakia; Jennifer L Guerriero; Salomon Manier; Michele Moschetta; Yuji Mishima; Aldo Roccaro; Alexandre Detappe; Chia-Jen Liu; Antonio Sacco; Daisy Huynh; Yu-Tzu Tai; Michael D Robbins; Jamil Azzi; Irene M Ghobrial
Journal:  Mol Cancer Ther       Date:  2018-04-13       Impact factor: 6.261

Review 2.  Microbiota in cancer development and treatment.

Authors:  Muhammad Hassan Raza; Kamni Gul; Abida Arshad; Naveeda Riaz; Usman Waheed; Abdul Rauf; Fahad Aldakheel; Shatha Alduraywish; Maqbool Ur Rehman; Muhammad Abdullah; Muhammad Arshad
Journal:  J Cancer Res Clin Oncol       Date:  2018-12-12       Impact factor: 4.553

3.  The liposome of trehalose dimycolate extracted from M. bovis BCG induces antitumor immunity via the activation of dendritic cells and CD8+ T cells.

Authors:  Masanobu Shiga; Jun Miyazaki; Kozaburo Tanuma; Yoshiyuki Nagumo; Takayuki Yoshino; Shuya Kandori; Hiromitsu Negoro; Takahiro Kojima; Ryota Tanaka; Naoko Okiyama; Yasuhiro Fujisawa; Miyuki Watanabe; Sho Yamasaki; Hideyasu Kiyohara; Makoto Watanabe; Taka-Aki Sato; Hideaki Tahara; Hiroyuki Nishiyama; Ikuya Yano
Journal:  Cancer Immunol Immunother       Date:  2021-02-11       Impact factor: 6.968

4.  Clinical practice guideline for image-guided multimode tumour ablation therapy in hepatic malignant tumours.

Authors:  G Z Wang; X H He; Y Wang; L C Xu; H Z Huang; Y H Wang; Z Shen; X D Qu; X Y Ding; J J Yang; W T Li
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

5.  PPP2R2B downregulation is associated with immune evasion and predicts poor clinical outcomes in triple-negative breast cancer.

Authors:  Zheng Li; Yaming Li; Xiaolong Wang; Qifeng Yang
Journal:  Cancer Cell Int       Date:  2021-01-06       Impact factor: 5.722

Review 6.  Drug development in the era of precision medicine.

Authors:  Sarah A Dugger; Adam Platt; David B Goldstein
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

7.  Association Between Inflammatory Diet Pattern and Risk of Colorectal Carcinoma Subtypes Classified by Immune Responses to Tumor.

Authors:  Li Liu; Reiko Nishihara; Zhi Rong Qian; Fred K Tabung; Daniel Nevo; Xuehong Zhang; Mingyang Song; Yin Cao; Kosuke Mima; Yohei Masugi; Yan Shi; Annacarolina da Silva; Tyler Twombly; Mancang Gu; Wanwan Li; Tsuyoshi Hamada; Keisuke Kosumi; Kentaro Inamura; Jonathan A Nowak; David A Drew; Paul Lochhead; Katsuhiko Nosho; Kana Wu; Molin Wang; Wendy S Garrett; Andrew T Chan; Charles S Fuchs; Edward L Giovannucci; Shuji Ogino
Journal:  Gastroenterology       Date:  2017-09-01       Impact factor: 22.682

8.  Profiling cancer testis antigens in non-small-cell lung cancer.

Authors:  Dijana Djureinovic; Björn M Hallström; Masafumi Horie; Johanna Sofia Margareta Mattsson; Linnea La Fleur; Linn Fagerberg; Hans Brunnström; Cecilia Lindskog; Katrin Madjar; Jörg Rahnenführer; Simon Ekman; Elisabeth Ståhle; Hirsh Koyi; Eva Brandén; Karolina Edlund; Jan G Hengstler; Mats Lambe; Akira Saito; Johan Botling; Fredrik Pontén; Mathias Uhlén; Patrick Micke
Journal:  JCI Insight       Date:  2016-07-07

9.  Ductal carcinoma in situ of the breast: immune cell composition according to subtype.

Authors:  Marie Colombe Agahozo; Mieke R van Bockstal; Floris H Groenendijk; Thierry P P van den Bosch; Pieter J Westenend; Carolien H M van Deurzen
Journal:  Mod Pathol       Date:  2019-08-02       Impact factor: 7.842

10.  Discovery and Characterization of Two Classes of Selective Inhibitors of the Suppressor of the TCR Signaling Family of Proteins.

Authors:  Weijie Zhou; Yue Yin; Emery Smith; Jacqueline Chou; Justin Shumate; Louis Scampavia; Timothy P Spicer; Nicholas Carpino; Jarrod B French
Journal:  ACS Infect Dis       Date:  2018-12-14       Impact factor: 5.084
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.